XM does not provide services to residents of the United States of America.

LexisNexis fends off appeal in patent case over lawyer billing software



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>REFILE-LexisNexis fends off appeal in patent case over lawyer billing software</title></head><body>

Refiles with updated company code in paragraph 1

By Blake Brittain

Nov 12 (Reuters) -Information technology company LexisNexis REL.L convinced a U.S. appeals court on Tuesday to uphold a ruling against a patent owner that accused the company of infringing a patent related totracking lawyers' billable hours.

The U.S. Court of Appeals for the Federal Circuit affirmed a lower court's decision that Realtime Tracker Inc's innovations in lawyer time tracking were unpatentable less than a week after hearing oral arguments on the case.

Realtime attorney Robert Goethals of Leichtman Law and LexisNexis attorney Oleg Khariton of Dinsmore & Shohl declined to comment.

Realtime sued Lexis in New York federal court in 2021 over a Realtime patent covering a computer system that two New York attorneys developed for tracking billable time automatically. It accused Lexis of infringing the patent with its Juris Suite Timer software.

Reuters News' parent company Thomson Reuters is a competitor of LexisNexis.

U.S. District Judge Paul Engelmayer sided with Lexis and dismissed the case last year, finding that Realtime's patent covered a patent-ineligible abstract idea. Realtime asked the Federal Circuit to reconsider the ruling, arguing in a court brief that the patent covered a "novel software invention" for improving computer functions.

A three-judge Federal Circuit panel had expressed some skepticism of Realtime's position during oral arguments last week.

"Can you do that same sort of tracking using a pen, paper and stopwatch?" U.S. Circuit Judge Tiffany Cunningham said.

The case is Realtime Tracker Inc v. Relx Inc d/b/a LexisNexis, U.S. Court of Appeals for the Federal Circuit, No. 23-1756.

For Realtime: Robert Goethals of Leichtman Law

For Lexis: Oleg Khariton of Dinsmore & Shohl

Read more:

LexisNexis fights patent appeal over lawyer billing software



Reporting by Blake Brittain in Washington

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.